Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American

Kidney Neoplasms Clinical Trial

Official title:

Renal Cell Cancer Registry in Latin American Clinical-phatological Characterization and Outcomes of Renal Cell Carcinoma in Latin America

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05184504
• Other study ID #: LACOG 1120
• Status: Recruiting
• Start date: September 1, 2022
• Est. completion date: June 14, 2026

Study information

• Verified date: March 2024
• Source: Latin American Cooperative Oncology Group
• Contact: Laura Mendonça
• Phone: +55 51 33845334
• Email: laura.mendonca[@]lacogcancerresearch.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Observational study, retrospective and prospective, of an analytical nature. Data will be collected from medical records and/or through contact with physicians and institutions (secondary data collection). Patients included retrospectively or prospectively will be followed during the data collection period for the evaluation of treatments and survival. No intervention is planned in this protocol.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 204
• Est. completion date: June 14, 2026
• Est. primary completion date: June 14, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients = 18 years of age;
• Proven histology of renal cell carcinoma (any subtype);
• Pathological diagnosis of renal cell carcinoma in January 2015 or later and new cases diagnosed during the period of recruitment of each center;
• Have the medical record available and suitable for collecting data on patient characteristics, treatment and outcome.

Exclusion Criteria:

• Synchronous or other primary tumor within the last 3 years (except thyroid cancer or non melanoma skin).

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Kidney Neoplasms

Intervention

Other:
• Observational study
This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Locations

Country	Name	City	State
Brazil	Hospital Porto Dias	Belém	Pará
Brazil	Onco-Vida Instituto Especializado de Oncologia	Brasília	Distrito Federal
Brazil	Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO)	Cachoeiro De Itapemirim	Espírito Santo
Brazil	Clinica Prognóstica - Centro de Pesquisa Clínica Onconeo	Campo Grande	Mato Grosso Do Sul
Brazil	ICTR - Instituto do Câncer e Transplante de Curitiba	Curitiba	Paraná
Brazil	Santa Casa de Misericórdia de Feira de Santana	Feira De Santana	Bahia
Brazil	Oncocentro Ceará (Rede D'or)	Fortaleza	Ceará
Brazil	Hospital Napoleão Laureano	João Pessoa	Paraíba
Brazil	CINPAM - Centro Integrado de Pesquisa da Amazônia	Manaus	Amazonas
Brazil	CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS	Porto Alegre	Rio Grande Do Sul
Brazil	CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas)	Rio De Janeiro
Brazil	NOB - Núcleo de Oncologia da Bahia (Oncoclínicas)	Salvador	Bahia
Brazil	Clínica de Hematologia e Oncologia Viver	Santa Maria	Rio Grande Do Sul
Brazil	Hospital do Câncer do Maranhão Dr. Tarquínio Lopes Filho	São Luís	Maranhão
Brazil	CPO - Centro Paulista de Oncologia (Oncoclínicas)	São Paulo
Brazil	Hemomed Instituto de Oncologia e Hematologia	São Paulo

Sponsors (2)

Lead Sponsor	Collaborator
Latin American Cooperative Oncology Group	Ipsen

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Build a real-life renal cell cancer database in Brazil and Latin America		2022
Secondary	Sociodemographic characteristics checklist	Describe sociodemographic characteristics: age at diagnosis, race, education, family income, occupation, personal habits, family history, comorbidities, treatment funding (public or private), treatment institution (public, private or philanthropic).	2022
Secondary	Clinicopathological characteristics of patients with renal cell cancer checklist	date of onset of symptoms, pre-treatment symptoms, histology, clinical and pathological stage, performance status, tests used in staging, date of diagnosis, site of metastases, complications clinics.	2022
Secondary	Characteristics of systemic treatment checklist	date of biopsy; dates, type and lines of drug treatment.	2022
Secondary	Time between diagnosis and start of treatment.	Characteristics of systemic treatment checklist	2022
Secondary	Causes of delay or discontinuation of each treatment checklist	Characteristics of systemic treatment	2022
Secondary	Progression-free survival in each therapeutic line		2022
Secondary	Overall survival		2022